Jinoos Yazdany, MD, MPH, Named Executive Director of AI Monitoring in Clinical Care

The Division of Clinical Informatics and Digital Transformation (DoC-IT) is pleased to announce that Jinoos Yazdany, MD, MPH, has been named the inaugural Executive Director of AI Monitoring in Clinical Care. In her new role, Jinoos will lead IMPACC—the Impact Monitoring Platform for Clinical Care—a pioneering collaboration between UCSF Health and DoC-IT.

As executive director, Jinoos will spearhead the development of the foundational components of IMPACC: an advanced, real-time AI monitoring platform designed to continuously evaluate the efficacy, safety, fairness, and overall value of AI tools deployed at UCSF Health. A central focus of her role will also be to expand access to data on AI implementations, ensuring that UCSF’s research community can leverage these data to drive innovative research.

In the near term, IMPACC will deploy robust, readily implementable metrics to ensure AI tools are safe and effective, while simultaneously building a research pipeline to pioneer new monitoring approaches. Beyond UCSF, the open-source AI-monitoring metrics developed by the IMPACC team will enable institutions nationwide to learn from and tailor evidence-based strategies to their own needs.

Drawing on her extensive background in epidemiology, health services research, clinical informatics, and implementation science, Jinoos is uniquely positioned to drive innovations that enhance patient care. She serves as chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital (ZSFG) and is the UCSF Alice Betts Endowed Professor of Medicine. As a rheumatologist specializing in systemic lupus, she practices at ZSFG and co-directs the UCSF Health Lupus Clinic.

Throughout her distinguished career, she has built and led large-scale collaborations, and her visionary leadership has consistently fostered innovation and improved patient outcomes. This has included developing multiple nationally endorsed quality measures in rheumatology, establishing a widely used national registry in rheumatology called RISE, and, during the pandemic, launching the COVID-19 Global Rheumatology Alliance that brought together scientists from over 40 countries.

IMPACC is a natural extension of this work. By bringing together researchers, clinicians, and health system leaders, she will foster collaboration, expand access to critical AI data, and develop new strategies for monitoring emerging technologies—including generative AI—ensuring they are deployed safely and equitably in clinical care.

“As AI becomes more deeply embedded in healthcare, we must take an active approach to monitoring,” Jinoos said. “IMPACC will be essential to ensuring these technologies are not only safe but also fair and truly beneficial for both patients and our health system. Our team aims to set the gold standard for AI oversight, ensuring these tools earn our trust and truly enhance patient care.”.”

Jinoos received her undergraduate degree from Stanford, her MD from UCLA, and her MPH from Harvard. She then completed her internal medicine residency and fellowship in rheumatology at UCSF.

We are thrilled to welcome Jinoos as she leads us into this exciting new chapter of AI-driven clinical care. IMPACC is made possible through the generous support of Ken and Kathy Hao. Jinoos will work closely with Sara Murray, MD, MAS, UCSF’s Chief Health AI Officer; Julia Adler-Milstein, PhD, Chief of DoC-IT; and Hossein Soleimani, PhD, Senior Data Scientist.